中枢神经系统环路在抑郁促进乳腺癌进程中的作用
作者简介:
吴迎朝，男，博士，住院医师，主要从事中医药治疗乳腺肿瘤的临床和基础研究，ORCID: 0000-0002-4810-0399
陈前军: 医学博士，主任中医师，博士生导师，博士后合作导师。广东省中医院副院长、广东省中医院珠海医院院长、广东省中医院乳腺病专科医院院长。广州中医药大学中医外科学学科带头人，广东省杰出青年医学人才、广州中医药大学千百十计划人才、广东省中医院拔尖人才、中华中医药学会乳腺病学会主任委员、中华中医药学会（乳腺病）科学传播专家团队首席科学传播专家、中华中医药学会名医名家科普工作室首席专家。主要从事中医药治疗乳腺肿瘤的临床和基础研究，依托中医证候全国重点实验室，紧扣林毅国医大师提出的乳腺癌“分期辩证”理论和“因郁致瘤”病机理论，创新性地提出情志相关乳腺癌的“脑-乳神经轴”理论，探讨中枢“脑-乳神经轴”与外周肿瘤免疫微环境调控机制。执笔制订多部国家指南与行业共识。近5年主持国家自然科学基金面上项目3项，获批广东省自然科学基金1项、广州市重点实验室项目1项以及校级课题4项。发表SCI收录论文17篇（单篇最高IF=9.756），获得广东省科技进步奖二等奖1项、中华中医药学会科学技术奖二等奖1项，获批专利3项
。
通讯作者:
Role of Central Nervous System Circuits in Promotion of Breast Cancer Progression by Depression
-
摘要:
随着神经科学与肿瘤学的发展，中枢神经系统环路对肿瘤的直接调控作用被逐渐揭示。越来越多的证据表明，靶向情绪相关脑区的治疗，可能在阻断抑郁促进乳腺癌进程中具有很大的潜力，其背后复杂的机制涉及抑郁产生及中枢神经系统环路对肿瘤的调控，然而，该研究领域尚缺乏系统性的总结。本文综述了中枢神经系统环路与抑郁产生、中枢神经系统与外周肿瘤神经联系、交感神经系统调控肿瘤免疫微环境的最新研究进展，系统梳理了中枢神经系统环路在抑郁促进乳腺癌进展中的潜在机理，以期为乳腺癌的综合治疗提出新的解决方法。
Abstract:With the development of neuroscience and oncology, the direct regulation effect of central nervous system circuits on tumors has been gradually revealed. Evidence indicates that the therapy targeting emotion-related encephalic regions may have great potential in blocking the promotion of breast cancer progression by depression. The underlying complex mechanisms involve the generation of depression and the regulation of tumors by central nervous system circuits. However, a systematic summary is lacking in this field. This article reviews the latest research progress of the central nervous system circuits and the generation of depression, the neural connection between the central nervous system and peripheral tumor, and the regulation of the tumor immune microenvironment by the sympathetic nervous system. It also systematically investigates the potential mechanism of the central nervous system circuit in the promotion of breast cancer progression by depression to establish new solutions for the comprehensive treatment of breast cancer.
-
Key words:
- Depression /
- Breast cancer /
- Neural circuit /
- Sympathetic nerve /
- Tumor immune microenvironment
-
0 引言
结直肠癌是全球第三大最常见的恶性肿瘤，也是癌症相关死亡的第二大原因[1]，给卫生保健系统带来了沉重的负担。结直肠息肉是正常结直肠黏膜表面的突出物，组织学上可分为腺瘤性和非腺瘤性息肉，而“正常黏膜-腺瘤-癌”路径被认为是结直肠癌的主要演变过程，涉及组织细胞内驱动突变的逐渐累积，最终发生癌变[2-3]。结直肠腺瘤性息肉进展为结直肠癌的发病率和死亡率显著增加，因此，通过结肠镜检查对腺瘤性息肉进行早期筛查并行内镜下切除可有效降低结直肠癌的发生风险。中老年人围手术期并发症发生率及死亡率增加，术后恢复期长，对生活质量影响大[3-4]，在早期发现和早期治疗结直肠腺瘤性息肉方面需更为重视。本文以我院就诊的中老年结直肠息肉患者为研究对象，评估不同病理类型息肉的临床和内镜特征，分析社会人口学、生活饮食习惯、临床病史、内镜特点等指标对腺瘤性息肉的影响，最终确定结直肠腺瘤性息肉的危险因素，以对高危人群进行充分的监测，为提高结直肠癌的早期筛查及诊疗水平提供依据。
1 资料与方法
1.1 研究人群
数据来源于2023年4月至2024年6月在首都医科大学附属北京友谊医院消化内镜中心行结肠镜检查及内镜下治疗的中老年患者，对以上患者进行相关问卷调查、实验室和结肠镜检查及息肉病理数据收集。本研究已经本院伦理委员会审核批准（2022-P2-401-01），所有患者均签署知情同意书。纳入标准：（1）年龄>45岁；（2）均自愿行结肠镜检查，且经病理检查确诊；（3）临床资料均完整无缺项。排除标准：（1）既往行下消化道外科手术；（2）妊娠患者；（3）正在参加其他临床研究，会影响本研究的搜集指标者。
1.2 数据收集
结肠镜检查前患者配合医生认真完成调查问卷的填写，内容包括患者姓名、年龄、性别、生活饮食习惯、慢性病史、简易精神状态评价量表（Mini-mental state examination, MMSE）等。身高和体重在内镜检查前规范测量，体重指数（Body mass index, BMI）由体重（kg）除以身高（m）的平方得出。高血压由患者自我报告的高血压病史确定。甘油三酯、血糖等空腹血液生化指标由医院检验科分析得出。益生菌是指食品中的活的有益微生物，包括双歧杆菌、乳杆菌、酪酸梭菌、布拉酵母菌、肠球菌、地衣芽孢杆菌和蜡样芽孢杆菌等。
所有患者均由经验丰富的消化内科医生使用电子结肠镜进行检查。患者在检查前一天分次口服聚乙二醇电解质散溶液以行肠道准备，检查时协助患者保持左侧卧位、双膝屈曲。结肠镜检查时准确记录息肉的数量、部位、形态、大小等信息，镜下取活检或根据患者实际情况选择合理治疗方案切除息肉，包括圈套器摘除、内镜下黏膜切除术、内镜黏膜下剥离术等。将息肉组织标本进行合理固定后送往病理科行病理检查，由经验丰富的病理科医生进行诊断。根据病理特点，炎性息肉、增生性息肉被定义为非腺瘤性息肉，而锯齿状腺瘤、管状腺瘤、管状绒毛状腺瘤、绒毛状腺瘤被定义为腺瘤性息肉。
1.3 统计学方法
数据采用R软件（4.2.2版）进行分析。正态分布的连续变量用均值和标准差表示，非正态分布的连续变量用中位数和四分位间距表示，计数资料数据用数量和百分比表示。多独立样本的组间比较时，分类变量采用卡方检验，正态分布的连续变量需采用方差分析，非正态分布的连续变量需采用Kruskal-Wallis检验。通过单因素及多因素Logistic回归分析对年龄、性别、BMI、生活饮食习惯、实验室数据、结肠镜病理检查结果等因素计算比值比（Odds ratio, OR）和95%CI。双侧P<0.05表示差异有统计学意义。
2 结果
2.1 结直肠息肉临床病理特征分析
共有1 527例45岁以上的结直肠息肉患者被纳入分析。经病理确诊，其中炎性息肉264例（17.3%），增生性息肉262例（17.2%），锯齿状腺瘤39例（2.6%），管状腺瘤926例（60.6%），管状绒毛状腺瘤33例（2.2%），绒毛状腺瘤3例（0.2%）。各病理分组下的临床和病理特征见表1，其中年龄、BMI、吸烟史、饮酒史、益生菌服用习惯、MMSE评分、息肉部位、息肉形态、息肉长径在各组间的差异均有统计学意义（均P<0.05）。
表 1 不同病理类型的结直肠息肉患者的基线特征Table 1 Baseline characteristics of patients with colorectal polyps of different pathological typesTotal Inflammatory
polypsHyperplastic
polypsSerrated
adenomasTubular
adenomasTubular villous
adenomasVillous
adenomasP Number 1 527 264 262 39 926 33 3 Gender(n(%)) 0.141 Male 826(54.1) 127(48.1) 142(54.2) 24(61.5) 518(55.9) 14(42.4) 1(33.3) Female 701(45.9) 137(51.9) 120(45.8) 15(38.5) 408(44.1) 19(57.6) 2(66.7) Age, mean(SD) 69.85(5.23) 69.29(4.49) 69.28(5.65) 69.44(4.45) 70.15(5.35) 71.03(4.58) 71.00(0.00) 0.047 BMI, mean(SD)(kg/m2) 24.44(3.34) 24.19(3.41) 24.33(3.06) 23.54(3.05) 24.68(3.38) 21.87(2.61) 24.03(1.86) <0.001 Smoking history(n(%)) 0.001 No 1117 (73.1)217(82.2) 202(77.1) 28(71.8) 643(69.4) 25(75.8) 2(66.7) Yes 410(26.9) 47(17.8) 60(22.9) 11(28.2) 283(30.6) 8(24.2) 1(33.3) Drinking history(n(%)) <0.001 No 1086 (71.1)216(81.8) 195(74.4) 29(74.4) 621(67.1) 23(69.7) 2(66.7) Yes 441(28.9) 48(18.2) 67(25.6) 10(25.6) 305(32.9) 10(30.3) 1(33.3) Hypertension(n(%)) 0.277 No 797(52.2) 143(54.2) 152(58.0) 19(48.7) 466(50.3) 15(45.5) 2(66.7) Yes 730(47.8) 121(45.8) 110(42.0) 20(51.3) 460(49.7) 18(54.5) 1(33.3) Triglyceride, mean(SD)
(mmol/L)1.44(0.76) 1.47(0.78) 1.47(0.79) 1.31(0.67) 1.44(0.75) 1.24(0.59) 1.69(0.40) 0.469 Fasting blood glucose,
mean(SD)(mmol/L)5.67(1.33) 5.64(1.46) 5.85(1.19) 6.01(1.50) 5.62(1.31) 5.47(1.43) 5.66(0.16) 0.081 Eat cereal(n(%)) 0.835 ≥4 times per week 572(37.5) 95(36.0) 96(36.6) 17(43.6) 350(37.8) 12(36.4) 2(66.7) <4 times per week 955(62.5) 169(64.0) 166(63.4) 22(56.4) 576(62.2) 21(63.6) 1(33.3) Eat fresh vegetables (n(%)) 0.686 ≥4 times per week 1412 (92.5)250(94.7) 240(91.6) 35(89.7) 853(92.1) 31(93.9) 3(100.0) <4 times per week 115(7.5) 14(5.3) 22(8.4) 4(10.3) 73(7.9) 2(6.1) 0(0.0) Eat fresh fruits(n(%)) 0.72 ≥4 times per week 1223 (80.1)213(80.7) 215(82.1) 32(82.1) 736(79.5) 24(72.7) 3(100.0) <4 times per week 304(19.9) 51(19.3) 47(17.9) 7(17.9) 190(20.5) 9(27.3) 0(0.0) Eat probiotics(n(%)) 0.027 ≥4 times per week 1363 (89.3)242(91.7) 223(85.1) 36(92.3) 834(90.1) 26(78.8) 2(66.7) <4 times per week 164(10.7) 22(8.3) 39(14.9) 3(7.7) 92(9.9) 7(21.2) 1(33.3) MMSE score, mean(SD) 28.76(2.21) 28.96(1.60) 28.99(1.61) 28.33(2.04) 28.70(2.38) 27.67(4.45) 28.00(1.00) 0.008 Polyp location(n(%)) <0.001 Ileocecal region 98(6.4) 21(8.0) 11(4.2) 7(17.9) 55(5.9) 3(9.1) 1(33.3) Ascending colon 279(18.3) 52(19.7) 29(11.1) 12(30.8) 179(19.3) 7(21.2) 0(0.0) Transverse colon 429(28.1) 62(23.5) 50(19.1) 9(23.1) 301(32.5) 7(21.2) 0(0.0) Descending colon 214(14.0) 39(14.8) 26(9.9) 5(12.8) 141(15.2) 3(9.1) 0(0.0) Sigmoid colon 321(21.0) 46(17.4) 91(34.7) 2(5.1) 172(18.6) 9(27.3) 1(33.3) Rectum 186(12.2) 44(16.7) 55(21.0) 4(10.3) 78(8.4) 4(12.1) 1(33.3) Polyp shape(n(%)) <0.001 Pedicled polyp 141(9.2) 20(7.6) 19(7.3) 2(5.1) 91(9.8) 9(27.3) 0(0.0) Sessile polyp 544(35.6) 59(22.3) 77(29.4) 16(41.0) 377(40.7) 14(42.4) 1(33.3) Flat polyp 790(51.7) 173(65.5) 162(61.8) 13(33.3) 433(46.8) 7(21.2) 2(66.7) Laterally
developmental polyp52(3.4) 12(4.5) 4(1.5) 8(20.5) 25(2.7) 3(9.1) 0(0.0) Polyp diameter,
mean(SD)(mm)7.54(6.80) 7.25(8.44) 5.24(2.68) 12.49(10.47) 7.87(6.41) 13.43(11.41) 4.67(2.89) <0.001 2.2 腺瘤性息肉的危险因素分析
在Logistic回归模型中，性别、年龄、BMI、吸烟史、饮酒史、高血压史、空腹甘油三酯水平、空腹血糖水平、饮食习惯、MMSE评分、息肉的病理特点均纳入分析范围。单变量回归分析显示，年龄更大、吸烟史、饮酒史、高血压病史及息肉长径是腺瘤性息肉的危险因素，而高MMSE评分（更良好的认知水平）、息肉部位为直肠及息肉形态为平坦型为保护性因素。经多变量模型调整后，结果显示：年龄更大（OR: 1.024，95%CI: 1.001~1.048，P=0.044）、BMI水平更高（OR: 1.046，95%CI: 1.008~1.087，P=0.020）和有吸烟史（OR: 1.493，95%CI: 1.035~2.158，P=0.032）的患者的结直肠息肉为腺瘤的风险显著升高，而高MMSE评分所代表的具有更好认知功能的患者结直肠息肉为非腺瘤性的可能性更大（OR: 0.929，95% CI: 0.871~0.984，P=0.017）。在息肉病理特征方面，病变部位在直肠（OR: 0.396，95%CI: 0.229~0.677，P=0.001）、平坦型（OR: 0.531，95%CI: 0.342~0.810，P=0.004）或侧向发育型（OR: 0.306，95%CI: 0.135~0.698，P=0.005）的息肉更多为非腺瘤性息肉，随着息肉大小的增加，病理为腺瘤性息肉的可能性显著增加（OR: 1.063，95%CI: 1.035~1.095，P<0.001），见表2。
表 2 腺瘤组和非腺瘤组单因素和多因素Logistic回归分析Table 2 Univariate and multivariate logistic regression analyses of adenoma and non-adenoma groupsVariables Univariable model Multivariable model OR 95%CI P OR 95%CI P Gander (Female) 0.834 0.675-1.031 0.094 1.168 0.892-1.530 0.258 Age 1.032 1.011-1.053 0.002 1.024 1.001-1.048 0.044 BMI 1.026 0.994-1.060 0.118 1.046 1.008-1.087 0.020 Smoking history 1.700 1.325-2.193 <0.001 1.493 1.035-2.158 0.032 Drinking history 1.726 1.354-2.212 <0.001 1.264 0.881-1.815 0.204 Hypertension 1.269 1.027-1.570 0.028 0.896 0.700-1.145 0.379 Triglyceride (mmol/L) 0.929 0.811-1.067 0.294 0.875 0.746-1.028 0.101 Fasting blood glucose (mmol/L) 0.936 0.866-1.012 0.096 0.944 0.867-1.029 0.182 Eat cereal (<4 times per week) 0.928 0.745-1.154 0.502 0.888 0.695-1.132 0.339 Eat fresh vegetables (<4 times per week) 1.166 0.781-1.774 0.461 1.653 1.003-2.769 0.052 Eat fresh fruits (<4 times per week) 1.132 0.868-1.483 0.365 0.887 0.634-1.245 0.485 Eat probiotics (<4 times per week) 0.874 0.627-1.229 0.433 0.800 0.555-1.160 0.234 MMSE score 0.922 0.865-0.975 0.008 0.929 0.871-0.984 0.017 Polyp location (Ascending colon) 1.185 0.717-1.935 0.501 1.216 0.721-2.027 0.457 Polyp location (Transverse colon) 1.372 0.847-2.191 0.191 1.368 0.828-2.231 0.214 Polyp location (Descending colon) 1.111 0.661-1.849 0.686 1.194 0.693-2.039 0.518 Polyp location (Sigmoid colon) 0.651 0.401-1.042 0.078 0.686 0.412-1.126 0.141 Polyp location (Rectum) 0.426 0.253-0.706 0.001 0.396 0.229-0.677 0.001 Polyp shape (Sessile polyp) 1.147 0.750-1.729 0.519 1.141 0.725-1.772 0.562 Polyp shape (Flat polyp) 0.519 0.346-0.765 0.001 0.531 0.342-0.810 0.004 Polyp shape (Laterally spreading polyp) 0.860 0.434-1.753 0.671 0.306 0.135-0.698 0.005 Polyp diameter 1.063 1.040-1.090 <0.001 1.063 1.035-1.095 <0.001 3 讨论
结直肠癌是世界发病率和死亡率最高的消化系统恶性肿瘤[1]，腺瘤性息肉被认为是大多数结直肠癌的前驱病变[5]，早期识别腺瘤性息肉并行内镜下治疗是预防结直肠癌的重要措施。本研究分析了中老年结直肠腺瘤性和非腺瘤性息肉患者的人口统计学、生活习惯、临床病史、实验室检查、内镜特征等信息。结果表明，年龄更大、体重指数更高、吸烟、息肉大小是腺瘤性息肉的独立危险因素，而患者认知功能更好、病变部位在直肠和平坦型或侧向发育型形态的息肉病理更可能为非腺瘤性。
本研究未发现腺瘤与非腺瘤患者间的性别差异。年龄是结直肠腺瘤发生的重要危险因素，结直肠息肉和结直肠癌的发病率一般随年龄增长而增加[6]。对无症状人群进行的结肠镜筛查研究表明，50岁人群的腺瘤患病率为25%~30%[7]。尸检研究发现，70岁人群的这一比例高达50%[8]，而20多岁或30岁人群的这一比例只有1%~4%[9]。结肠镜检查是检测结直肠息肉和结直肠癌最有效的方式，基于多项研究结果，美国癌症协会指南建议根据患者的偏好从45岁开始进行结肠镜筛查，以早期发现结直肠癌和结直肠腺瘤息肉[10]。因此，我们将研究人群的年龄限制在45岁及以上的中老年人，结果表明，与先前的结果一致，年龄越大的结直肠息肉患者越容易发生腺瘤的病理改变。
既往多项研究报道，肥胖与结直肠腺瘤的发生和复发密切相关[11-12]，而减重可以有效降低腺瘤发生风险[13]。本研究结果也表明，代表超重和肥胖的高BMI水平会增加腺瘤发生的风险。这其中的机制尚不明确，可能与肥胖伴随的胰岛素抵抗通过胰岛素和胰岛素样生长因子轴导致有丝分裂和抗凋亡信号转导异常相关。此外，肥胖也反映了一种慢性低度炎性反应状态，从而增加息肉癌变的风险[14]。
吸烟是导致结直肠癌的公认的主要风险因素。此前多项研究发现，吸烟与腺瘤性息肉以及晚期肿瘤如浸润性结直肠癌之间存在密切关联[12]，这与我们的研究结果类似。每日吸烟数量、吸烟时间与结直肠息肉的风险存在剂量-反应关系[15]。烟草中含有多种致癌物质，先前的研究揭示了一些吸烟与结直肠腺瘤发生的潜在机制，如相关基因的甲基化减少[16]、致癌物代谢酶的基因变异[17]、DNA修复基因EXO1和ATM的多态性[18]、错配修复酶的突变[19]、XPC的多态性[20]等。一项荟萃分析表示，酒精与结直肠腺瘤的风险增加有关，这种关联似乎在欧洲的研究中更为显著[21]。本研究并没有显示酒精对结直肠腺瘤发生的影响，这可能与不同地区研究人群的基因和生活方式差异相关。
本研究结果表明，MMSE代表的认知功能状态与是否为腺瘤性息肉有显著相关性，而因果关系尚不明确，既往暂无分析认知功能与结直肠腺瘤发生的相关性研究。但已有多项研究表示，结直肠癌、炎性反应性肠病等与认知功能和精神疾病有密切关联，微生物群-肠-脑轴可能在其中起重要作用，肠道微生物群组成失调和肠道屏障功能异常可能参与了重要的病理机制[22]。这一点，未来还需要大样本量的随机对照试验来证实。
除人群特征外，息肉特征也会影响腺瘤发生的风险。既往有多项研究报道息肉的大小为结直肠息肉恶性肿瘤的独立预测因子[23-24]。直径为1厘米的腺瘤发生腺癌的风险为1%，直径为1~2厘米的腺瘤为10%，而直径大于2厘米的腺瘤发生腺癌的风险为50%[25]。本研究结果表明，息肉大小也为腺瘤病理的独立危险因素。因此，对于直径较大的息肉更应警惕，尽早行内镜下切除以避免发生癌变。本研究中，息肉为平坦型和侧向发育型时较带蒂息肉病理为腺瘤的风险更低，发展为结直肠癌的可能性更小，这与既往的研究结果一致[26]。但近年来，有学者认为扁平息肉可能通过特殊的机制发生进展期肿瘤性病变[27]，因此扁平状息肉的潜在恶变可能也需警惕。本研究结果提示位于直肠的息肉多为非腺瘤性息肉。既往研究认为右半结肠腺瘤发生率更高，结直肠癌的发生位置也逐渐向右侧转移[28]，这可能与肠内容物在右半结肠中停留时间较长，使致癌物质和炎性反应介质长时间刺激而发展成腺瘤性息肉相关[29-30]，但本研究未发现腺瘤性息肉在结肠各节段发生率的差异。
本研究也存在一些局限性。首先，研究是单中心横断面研究，样本量有限，纳入分析的变量不够全面，可能会遗漏重要的指标。其次，患者的吸烟史、饮酒史、饮食习惯和高血压病史等数据来自自我报告的问卷调查，可能会造成回忆偏倚，从而对结果产生潜在影响。
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：吴迎朝：文章撰写梁裕琪：文章修改与编辑左 谦：文章选题、撰写指导陈前军：文章审校及修改 -
[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
[2] 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. [Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231.] doi: 10.3760/cma.j.cn112152-20240119-00035 Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231. doi: 10.3760/cma.j.cn112152-20240119-00035
[3] Tang M, Su Z, He Y, et al. Physical symptoms and anxiety and depression in older patients with advanced cancer in China: a network analysis[J]. BMC Geriatr, 2024, 24(1): 185. doi: 10.1186/s12877-024-04788-7
[4] Cai Y, Zhaoxiong Y, Zhu W, et al. Association between sleep duration, depression and breast cancer in the United States: a national health and nutrition examination survey analysis 2009-2018[J]. Ann Med, 2024, 56(1): 2314235. doi: 10.1080/07853890.2024.2314235
[5] Wang X, Wang N, Zhong L et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282, 203 patients[J]. Mol Psychiatry, 2020, 25(12): 3186-3197. doi: 10.1038/s41380-020-00865-6
[6] 井含光, 司徒红林, 朱华宇, 等. 林毅“六郁治乳”理论在乳腺病诊治中的应用[J]. 广州中医药大学学报, 2021, 38(8): 1714-1718. [Jing HG, Situ HL, Zhu HY, et al. Application of LIN Yi’s Six Kinds of Stagnancy Theory for Breast in the Treatment of Breast Diseases[J]. Guangzhou Zhong Yi Yao Da Xue Xue Bao, 2021, 38(8): 1714-1718.] Jing HG, Situ HL, Zhu HY, et al. Application of LIN Yi’s Six Kinds of Stagnancy Theory for Breast in the Treatment of Breast Diseases[J]. Guangzhou Zhong Yi Yao Da Xue Xue Bao, 2021, 38(8): 1714-1718.
[7] Hong Y, Zhang L, Liu N et al. The Central Nervous Mechanism of Stress-Promoting Cancer Progression[J]. Int J Mol Sci, 2022, 23(20): 12653. doi: 10.3390/ijms232012653
[8] Eckerling A, Ricon-Becker I, Sorski L, et al. Stress and cancer: mechanisms, significance and future directions[J]. Nat Rev Cancer, 2021, 21(12): 767-785. doi: 10.1038/s41568-021-00395-5
[9] Cui B, Peng F, Lu J, et al. Cancer and stress: NextGen strategies[J]. Brain Behav Immun, 2021, 93: 368-383. doi: 10.1016/j.bbi.2020.11.005
[10] Zhang L, Pan J, Chen W, et al. Chronic stress-induced immune dysregulation in cancer: implications for initiation, progression, metastasis, and treatment[J]. Am J Cancer Res, 2020, 10(5): 1294-1307.
[11] Li H, Kawatake-Kuno A, Inaba H, et al. Discrete prefrontal neuronal circuits determine repeated stress-induced behavioral phenotypes in male mice[J]. Neuron, 2024, 112(5): 786-804. e8.
[12] Rakotobe M, Fjerdingstad N, Ruiz-Reig N, et al. Central role of the habenulo-interpeduncular system in the neurodevelopmental basis of susceptibility and resilience to anxiety in mice[J]. Neurobiol Dis, 2024, 191: 106392. doi: 10.1016/j.nbd.2023.106392
[13] Xiong SY, Wen HZ, Dai LM, et al. A brain-tumor neural circuit controls breast cancer progression in mice[J]. J Clin Invest, 2023, 133(24): e167725. doi: 10.1172/JCI167725
[14] Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions[J]. Mol Psychiatry, 2018, 23(2): 335-343. doi: 10.1038/mp.2016.167
[15] Lach G, Schellekens H, Dinan TG, et al. Anxiety, Depression, and the Microbiome: A Role for Gut Peptides[J]. Neurotherapeutics, 2018, 15(1): 36-59. doi: 10.1007/s13311-017-0585-0
[16] Boku S, Nakagawa S, Toda H, et al. Neural basis of major depressive disorder: Beyond monoamine hypothesis[J]. Psychiatry Clin Neurosci, 2018, 72(1): 3-12. doi: 10.1111/pcn.12604
[17] Krishnan V, Nestler EJ. The molecular neurobiology of depression[J]. Nature, 2008, 455(7215): 894-902. doi: 10.1038/nature07455
[18] Keiflin R, Janak PH. Dopamine Prediction Errors in Reward Learning and Addiction: From Theory to Neural Circuitry[J]. Neuron, 2015, 88(2): 247-263. doi: 10.1016/j.neuron.2015.08.037
[19] Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders[J]. Nat Rev Neurosci, 2013, 14(9): 609-625.
[20] Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression[J]. Arch Gen Psychiatry, 2007, 64(3): 327-337. doi: 10.1001/archpsyc.64.3.327
[21] Covington HR, Lobo MK, Maze I, et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex[J]. J Neurosci, 2010, 30(48): 16082-16090. doi: 10.1523/JNEUROSCI.1731-10.2010
[22] Mayberg HS. Targeted electrode-based modulation of neural circuits for depression[J]. J Clin Invest, 2009, 119(4): 717-725. doi: 10.1172/JCI38454
[23] Teissier A, Le Magueresse C, Olusakin J, et al. Early-life stress impairs postnatal oligodendrogenesis and adult emotional behaviour through activity-dependent mechanisms[J]. Mol Psychiatry, 2020, 25(6): 1159-1174. doi: 10.1038/s41380-019-0493-2
[24] Son H, Baek JH, Go BS, et al. Glutamine has antidepressive effects through increments of glutamate and glutamine levels and glutamatergic activity in the medial prefrontal cortex[J]. Neuropharmacology, 2018, 143: 143-152. doi: 10.1016/j.neuropharm.2018.09.040
[25] Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions[J]. Mol Psychiatry, 2020, 25(11): 2742-2758. doi: 10.1038/s41380-020-0685-9
[26] Warden MR, Selimbeyoglu A, Mirzabekov JJ, et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge[J]. Nature, 2012, 492(7429): 428-432. doi: 10.1038/nature11617
[27] Geddes SD, Assadzada S, Lemelin D, et al. Target-specific modulation of the descending prefrontal cortex inputs to the dorsal raphe nucleus by cannabinoids[J]. Proc Natl Acad Sci U S A, 2016, 113(19): 5429-5434. doi: 10.1073/pnas.1522754113
[28] Srejic LR, Wood KM, Zeqja A, et al. Modulation of serotonin dynamics in the dorsal raphe nucleus via high frequency medial prefrontal cortex stimulation[J]. Neurobiol Dis, 2016, 94: 129-138. doi: 10.1016/j.nbd.2016.06.009
[29] Wise RA. Dopamine, learning and motivation[J]. Nat Rev Neurosci, 2004, 5(6): 483-494. doi: 10.1038/nrn1406
[30] Zhang H, Chaudhury D, Nectow AR, et al. alpha(1)- and beta(3)-Adrenergic Receptor-Mediated Mesolimbic Homeostatic Plasticity Confers Resilience to Social Stress in Susceptible Mice[J]. Biol Psychiatry, 2019, 85(3): 226-236. doi: 10.1016/j.biopsych.2018.08.020
[31] He F, Zhang P, Zhang Q, et al. Dopaminergic Projection from Ventral Tegmental Area to Substantia Nigra Pars Reticulata Mediates Chronic Social Defeat Stress-Induced Hypolocomotion[J]. Mol Neurobiol, 2021, 58(11): 5635-5648. doi: 10.1007/s12035-021-02522-7
[32] Root DH, Melendez RI, Zaborszky L, et al. The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors[J]. Prog Neurobiol, 2015, 130: 29-70. doi: 10.1016/j.pneurobio.2015.03.005
[33] Neumeister A, Wood S, Bonne O, et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects[J]. Biol Psychiatry, 2005, 57(8): 935-937. doi: 10.1016/j.biopsych.2005.01.016
[34] Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures?[J]. Neuron, 2010, 65(1): 7-19. doi: 10.1016/j.neuron.2009.11.031
[35] Zhang TR, Larosa A, Di Raddo ME, et al. Negative Memory Engrams in the Hippocampus Enhance the Susceptibility to Chronic Social Defeat Stress[J]. J Neurosci, 2019, 39(38): 7576-7590. doi: 10.1523/JNEUROSCI.1958-18.2019
[36] Lin S, Du Y, Xia Y, et al. Advances in optogenetic studies of depressive-like behaviors and underlying neural circuit mechanisms[J]. Front Psychiatry, 2022, 13: 950910. doi: 10.3389/fpsyt.2022.950910
[37] Shi DD, Guo JA, Hoffman HI, et al. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities[J]. Lancet Oncol, 2022, 23(2): e62-e74. doi: 10.1016/S1470-2045(21)00596-9
[38] Monje M, Borniger JC, D'Silva NJ, et al. Roadmap for the Emerging Field of Cancer Neuroscience[J]. Cell, 2020, 181(2): 219-222. doi: 10.1016/j.cell.2020.03.034
[39] Zhao CM, Hayakawa Y, Kodama Y, et al. Denervation suppresses gastric tumorigenesis[J]. Sci Transl Med, 2014, 6(250): 250ra115.
[40] Szpunar MJ, Burke KA, Dawes RP, et al. The antidepressant desipramine and alpha2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure[J]. Cancer Prev Res (Phila), 2013, 6(12): 1262-1272. doi: 10.1158/1940-6207.CAPR-13-0079
[41] Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression[J]. Science, 2013, 341(6142): 1236361. doi: 10.1126/science.1236361
[42] Kamiya A, Hayama Y, Kato S, et al. Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression[J]. Nat Neurosci, 2019, 22(8): 1289-1305. doi: 10.1038/s41593-019-0430-3
[43] Tye KM, Prakash R, Kim SY, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety[J]. Nature, 2011, 471(7338): 358-362. doi: 10.1038/nature09820
[44] Muscatell KA, Eisenberger NI, Dutcher JM, et al. Links between inflammation, amygdala reactivity, and social support in breast cancer survivors[J]. Brain Behav Immun, 2016, 53: 34-38. doi: 10.1016/j.bbi.2015.09.008
[45] Yoshikawa E, Matsuoka Y, Yamasue H, et al. Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis[J]. Biol Psychiatry, 2006, 59(8): 707-712. doi: 10.1016/j.biopsych.2005.08.018
[46] Paretkar T, Dimitrov E. The Central Amygdala Corticotropin-releasing hormone (CRH) Neurons Modulation of Anxiety-like Behavior and Hippocampus-dependent Memory in Mice[J]. Neuroscience, 2018, 390: 187-197. doi: 10.1016/j.neuroscience.2018.08.019
[47] Flandreau EI, Bourke CH, Ressler KJ, et al. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala[J]. Psychoneuroendocrinology, 2013, 38(8): 1349-1361. doi: 10.1016/j.psyneuen.2012.11.020
[48] Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response![J]. Crit Care, 2013, 17(2): 305. doi: 10.1186/cc12514
[49] Xiang HB, Liu C, Liu TT, et al. Central circuits regulating the sympathetic outflow to lumbar muscles in spinally transected mice by retrograde transsynaptic transport[J]. Int J Clin Exp Pathol, 2014, 7(6): 2987-2997.
[50] Horvath K, Juhasz B, Kuti D, et al. Recruitment of Corticotropin-Releasing Hormone (CRH) Neurons in Categorically Distinct Stress Reactions in the Mouse Brain[J]. Int J Mol Sci, 2023, 24(14): 11736. doi: 10.3390/ijms241411736
[51] Maruyama NO, Mitchell NC, Truong TT, et al. Activation of the hypothalamic paraventricular nucleus by acute intermittent hypoxia: Implications for sympathetic long-term facilitation neuroplasticity[J]. Exp Neurol, 2019, 314: 1-8. doi: 10.1016/j.expneurol.2018.12.011
[52] Chandrasekar G, Lauter G, Hauptmann G. Distribution of corticotropin-releasing hormone in the developing zebrafish brain[J]. J Comp Neurol, 2007, 505(4): 337-351. doi: 10.1002/cne.21496
[53] Dimitrov EL, DeJoseph MR, Brownfield MS, et al. Involvement of neuropeptide Y Y1 receptors in the regulation of neuroendocrine corticotropin-releasing hormone neuronal activity[J]. Endocrinology, 2007, 148(8): 3666-3673. doi: 10.1210/en.2006-1730
[54] Vega-Rivera NM, Estrada-Camarena E, Azpilcueta-Morales G, et al. Chronic Variable Stress and Cafeteria Diet Combination Exacerbate Microglia and c-fos Activation but Not Experimental Anxiety or Depression in a Menopause Model[J]. Int J Mol Sci, 2024, 25(3): 1455. doi: 10.3390/ijms25031455
[55] Jiang Y, Hu Y, Yang Y, et al. Tong-Xie-Yao-Fang promotes dendritic cells maturation and retards tumor growth in colorectal cancer mice with chronic restraint stress[J]. J Ethnopharmacol, 2024, 319(Pt 1): 117069.
[56] Wang J, Sun L, You J, et al. Role and mechanism of PVN-sympathetic-adipose circuit in depression and insulin resistance induced by chronic stress[J]. EMBO Rep, 2023, 24(12): e57176. doi: 10.15252/embr.202357176
[57] Ruyle BC, Lima-Silveira L, Martinez D, et al. Paraventricular nucleus projections to the nucleus tractus solitarii are essential for full expression of hypoxia-induced peripheral chemoreflex responses[J]. J Physiol, 2023, 601(19): 4309-4336. doi: 10.1113/JP284907
[58] Zhou J, Zhang B, Zhou X, et al. Electroacupuncture pretreatment mediates sympathetic nerves to alleviate myocardial ischemia-reperfusion injury via CRH neurons in the paraventricular nucleus of the hypothalamus[J]. Chin Med, 2024, 19(1): 43. doi: 10.1186/s13020-024-00916-y
[59] Yoshida S, Hamada Y, Narita M, et al. Elucidation of the mechanisms underlying tumor aggravation by the activation of stress-related neurons in the paraventricular nucleus of the hypothalamus[J]. Mol Brain, 2023, 16(1): 18. doi: 10.1186/s13041-023-01006-0
[60] Ji NN, Li ZY, Cao S, et al. Neuroinflammation in the paraventricular nucleus of the hypothalamus precipitates visceral pain induced by pancreatic cancer in mice[J]. J Gastrointest Oncol, 2024, 15(1): 468-477. doi: 10.21037/jgo-24-42
[61] Iqbal NJ, Schwartz GJ, Zhao H, et al. Cyclin-dependent kinase 4/6 inhibitors require an arcuate-to-paraventricular hypothalamus melanocortin circuit to treat diet-induced obesity[J]. Am J Physiol Endocrinol Metab, 2021, 320(3): E467-E474. doi: 10.1152/ajpendo.00386.2020
[62] Ye Y, Xie T, Amit M. Targeting the Nerve-Cancer Circuit[J]. Cancer Res, 2023, 83(15): 2445-2447. doi: 10.1158/0008-5472.CAN-23-1754
[63] Hu J, Chen W, Shen L, et al. Crosstalk between the peripheral nervous system and breast cancer influences tumor progression[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(6): 188828. doi: 10.1016/j.bbcan.2022.188828
[64] Xu Y, Yan J, Tao Y, et al. Pituitary hormone alpha-MSH promotes tumor-induced myelopoiesis and immunosuppression[J]. Science, 2022, 377(6610): 1085-1091. doi: 10.1126/science.abj2674
[65] Zhang X, Lei B, Yuan Y, et al. Brain control of humoral immune responses amenable to behavioural modulation[J]. Nature, 2020, 581(7807): 204-208. doi: 10.1038/s41586-020-2235-7
[66] Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-2007)[J]. Brain Behav Immun, 2007, 21(6): 736-745. doi: 10.1016/j.bbi.2007.03.008
[67] Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses[J]. Ann Surg, 2011, 253(4): 798-810. doi: 10.1097/SLA.0b013e318211d7b5
[68] Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer[J]. Cancer Res, 2010, 70(18): 7042-7052. doi: 10.1158/0008-5472.CAN-10-0522
[69] Qin JF, Jin FJ, Li N, et al. Adrenergic receptor beta2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment[J]. BMB Rep, 2015, 48(5): 295-300. doi: 10.5483/BMBRep.2015.48.5.008
[70] Ben-Eliyahu S, Shakhar G, Page GG, et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors[J]. Neuroimmunomodulation, 2000, 8(3): 154-164. doi: 10.1159/000054276
[71] Mohammadpour H, O'Neil R, Qiu J, et al. Blockade of Host beta2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs[J]. J Immunol, 2018, 200(7): 2479-2488. doi: 10.4049/jimmunol.1701752
[72] Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune responses after surgical treatment for regional breast cancer[J]. J Natl Cancer Inst, 1998, 90(1): 30-36. doi: 10.1093/jnci/90.1.30
[73] Silva D, Quintas C, Goncalves J, et al. Contribution of adrenergic mechanisms for the stress-induced breast cancer carcinogenesis[J]. J Cell Physiol, 2022, 237(4): 2107-2127. doi: 10.1002/jcp.30707
[74] Mohammadpour H, MacDonald CR, Qiao G, et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells[J]. J Clin Invest, 2019, 129(12): 5537-5552. doi: 10.1172/JCI129502
[75] Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth[J]. Oncotarget, 2015, 6(6): 4266-4273. doi: 10.18632/oncotarget.2887
[76] Setordzi P, Chang X, Liu Z, et al. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy[J]. Eur J Pharmacol, 2021, 895: 173867. doi: 10.1016/j.ejphar.2021.173867
[77] Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy[J]. Cell Res, 2017, 27(1): 109-118. doi: 10.1038/cr.2016.151
[78] Campbell JP, Karolak MR, Ma Y, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice[J]. PLoS Biol, 2012, 10(7): e1001363. doi: 10.1371/journal.pbio.1001363
下载:
计量
- 文章访问数: 551
- HTML全文浏览量: 2208
- PDF下载量: 330
